Sign In   |   Register

Breaking News:

8-15-18 Trickle Research Issues Research Note
Command Center, Inc.  
12-24 Month Price Target $9.60

Click Here for Research Note

8-16-18 Trickle Research Issues Research Note
Social Reality, Inc.  
12-24 Month Price Target $8.50

Click Here for Research Note

Consilium Global Research Issues
Quarterly Update 8-7-18
Zynex, Inc. 
Price Target $7.00
    Click Here>>

8-1-18 Trickle Research Issues Research Note
Social Reality, Inc. 
12-24 Month Price Target $7.50

Click Here for Research Note

05-31-18 Trickle Research Initiates Research of
Petroshare Corp 
12-24 Month Price Target $3.20

Click Here for Research Report

July-5-18 Greenridge Global Equity Research
Issues Updates Fullshare Holdings, Ltd. 
Click Here>>

Greenridge Global Equity Research
Issues Updates 6-4-18
Guangdong Land Holdings, Ltd. Click Here>>

Trickle Research update of
Assure Holdings, Corp  5-29-18
12-24 Month Price Target Suspended
  Click Here>>

Trickle Research earnings update of New Jersey Mining, Inc.   NJMC  5-17-18
12-24 Month Price Target $.30
  Click Here>>

Consilium Global Research Issues
Quarterly Update 5-15-18
Zynex, Inc.
Price Target $7.00
    Click Here>>

Trickle Research update of
Command Center, Inc.  5-15-18
12-24 Month Price Target $9.60
  Click Here>>

Greenridge Global Equity Research
Issues Updates 5-3-18
Guangdong Land Holdings, Ltd. Click Here>>

Trickle Research update of
AzurRx Biopharma, Inc.  5-2-18
12-24 Month Price Target $10.25
   Click Here>>

Trickle Research update of
AzurRx Biopharma, Inc.  4-16-18
12-24 Month Price Target $10.25
   Click Here>>

Trickle Research Earnings Update Q-4
Social Reality, Inc. SRAX
12 - 24 month Price Target: $7.50
Click Here>>

Trickle Research Initiates Coverage 4-6-18 for:
Camino Minerals CAMZF
12-24 Month Price Target $.90 

For full Research report >> Click Here

Greenridge Global Equity Research
Issues Updates 4-10-18
Guangdong Land Holdings, Ltd. Click Here>>

Consilium Global Research Issues Quarterly Update 3-8-18
Price Target $7.00
>> Click Here

Feb 2- 2018
Trickle Research Initiates Coverage
AzurRx Biopharma, Inc. 12-24 Month Target $10.25
Click Here>>

Consilium Global Research Initiates Coverage 12-5-17
Price target $6.00

>>For Full Research Report  >>Read More

Feb 18-2018
Trickle Research Issues Research Note
New Jersey Mining, Inc.
Click Here>>

Feb-2-2018
Greenridge Global Equity Research
Issues Updates
Fullshare Holdings, Ltd. 
Click Here>>

January 25-2018

Trickle Research issues Research Update
Endurance Exploration Group, Inc. (EXPL-OTC)
Click Here >>



 

  Black Swan Research
Research Coverage 7-18
SMM is now hosting Equity Research and updates from top tier research providers:
          
   Catalyst Research  
 Trickle Research
Click here to Subscribe to Trickle Research 
 Falcon Strategic Research
 Consilium Global Research
 ValuEngine
 Click Here to Subscribe to Black Swan Research
              

Black Swan Newsletter

SUBSCRIBE TO THE NEWSLETTER BELOW






 

July 2018

Click here to view

Our goal with the Black Swan Connection is to provide our subscribers, investors and financial professional compatriots outstanding investment insight that is a step above and outside of what will normally be found in mainstream financial press. To that end we have brought together seasoned, successful, and some of the brightest professionals in their respective fields to provide the articles and advice that is based on decades of practice in the field.

 

Breaking News

Falcon Strategic Research issues Research Update to Strong Buy 7-17-18
6 Month Price target Range $1.00 to $1.30
For Research Update Click Here >>

Greenridge Global Equity Research
Issues Updates 6-4-18
Acquisitions Look to be an accretive deal for shareholders

Guangdong Land Holdings, Ltd. 
Click Here>>

 

Featured Article

Stock Buybacks: In the Crosshairs of the SEC

-or-

The Canary in the Coal Mine?

By: Dave Lavigne

Just recently SEC commissioner Robert J. Jackson Jr. gave a speech to the Center for American Progress wherein he questioned the current rules regarding corporate stock buybacks and perhaps the practice in general, even calling for an open comment period regarding the issue.  Specifically, for the policy wonks, he referred to Rule 10b-18, which the SEC adopted in 1982.  As the Commission notes:

In 1982, the Commission adopted Rule 10b-18, which provides that an issuer will not be deemed to have violated Sections 9(a)(2) and 10(b) of the Exchange Act, and Rule 10b-5 under the Exchange Act, solely by reason of the manner, timing, price, or volume of its repurchases, if the issuer repurchases its common stock in the market in accordance with the safe harbor conditions. Rule 10b-18's safe harbor conditions are designed to minimize the market impact of the issuer's repurchases, thereby allowing the market to establish a security's price based on independent market forces without undue influence by the issuer.

Just to edify, 10b-18 was established as a framework to allow corporations a “Safe Harbor” from violations of Rule 10b-5 when repurchasing their shares in the public market. I believe, Rule 10b-5 was adopted in the early 1940’s  following the Commission’s recognition that the “employment of manipulative and deceptive practices" might apply to the purchase of securities as opposed to just the sale of securitiesAs a result,  Rule 10b-5 is often the hook for insider trading violations.

Read Complete Article

 

 


InvestorsHub News Wire:

 

 

 

Weekly Update: August 6th, 2018

Latest Happenings

esla- TSLA  $346.80

Great Update from ValuEngine 8-8-18

We have been tracking Tesla for a while here. As long-time readers know, we are definitely on the side of the shorts. Our models typically rate this stock a SELL, and despite the high share prices and the long-term trend, we cannot shake the feeling that something is wrong here.

Tesla, despite the massive valuation, has NEVER made a profit–and it most certainly isn’t Amazon, so that argument doesn’t fly with us. We believe Elon Musk benefits from a level of “fanboy” worship we haven’t seen since Steve Jobs died. We believe that all other Musk-linked activities–hyper loops, battery projects and rocket launches, serve as little more than PR to justify the share price of Tesla and hype the stock.

However–to paraphrase a wise trader, when you’re short you can definitely go broke even if you’re right. And so far, the shorts here have taken a bath. Musk seems to take their bets as a personal affront, and recent events show he may be taking actions to make their positions as expensive as possible.

complete report here

 

Breaking News

Consilium Global Research Issues Quarterly Update 8-7-18
Price Target $7.00 
>> For Quarterly Update >> Read MoreZynex is the leading provider of Electrotherapy Medical Devices used for pain management and rehabilitation. The company is also pioneering development of an Innovative Blood Volume Monitor.


 

 

 

Community Search
Sign In